The litigation targets a series of stock price collapses triggered by consecutive earnings disappointments. In November 2025, Doximity shares plummeted 13.25% after the company signaled an impending slowdown in ad spending. The decline deepened on February 6, 2026, when the firm reported decelerating sales and shrinking net income, causing a 16.78% single-day drop to $27.73 per share.

The final blow arrived in May 2026, when Doximity failed to meet its already lowered revenue guidance and issued a pessimistic outlook for the 2027 fiscal year. The stock fell another 23% to $18.01, prompting multiple analyst downgrades. Investors seeking to participate in the legal action can contact Danielle Peyton at Pomerantz LLP to formalize their claims before the November deadline.